Related Experiment Video

Updated: May 12, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI)

Paloma Bermejo-Bescós1, Sagrario Martín-Aragón, Karim Jiménez-Aliaga

  • 1Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040, Madrid, Spain. bescos@farm.ucm.es

Neurochemical Research
|April 12, 2013
PubMed

Insights

Platelet amyloid precursor protein (APP) metabolism markers show distinct patterns in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients, offering potential for early AD detection at the MCI stage.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) patients exhibit faster cognitive decline and increased dementia risk.
  • Blood molecular biomarkers are crucial for prognostic assessment in Alzheimer's disease (AD).

Purpose of the Study:

  • To evaluate platelet amyloid precursor protein (APP) metabolism in MCI and AD patients.
  • To determine the prognostic value of APP metabolism variations for predicting AD in MCI patients.

Main Methods:

  • Western blot analysis of APP, BACE1, PS1, and ADAM-10 protein levels in platelets.
  • Assay of BACE1 and γ-secretase enzyme activities in platelet samples.
  • Comparison of healthy elderly, MCI, and AD patient groups.

Main Results:

  • Reduced APP levels in MCI and AD patients compared to controls.
  • Increased ADAM-10 levels in both MCI and AD groups.
  • Elevated BACE1 and γ-secretase activities in both MCI and AD groups, with higher ADAM-10/BACE1 ratio in MCI vs. AD.

Conclusions:

  • Platelet APP processing markers show both similarities and differences between MCI and AD.
  • Further research with larger, diverse cohorts is needed to establish a diagnostic signature for early AD detection in MCI.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...